Vivo Capital’s Harmony Biosciences HRMY Stock Holding History

Vivo Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,606,247	Closed	-$104M	–	45
2024 Q3	$104M	Hold	2,606,247	–	–	8.63%	3
2024 Q2	$78.6M	Hold	2,606,247	–	–	7.26%	3
2024 Q1	$87.5M	Hold	2,606,247	–	–	6.88%	3
2023 Q4	$84.2M	Hold	2,606,247	–	–	6.89%	4
2023 Q3	$85.4M	Hold	2,606,247	–	–	9.36%	3
2023 Q2	$91.7M	Hold	2,606,247	–	–	6.33%	2
2023 Q1	$85.1M	Hold	2,606,247	–	–	5.9%	4
2022 Q4	$144M	Sell	2,606,247 -794,014	-23%	-$43.7M	16.53%	1
2022 Q3	$151M	Sell	3,400,261 -693,524	-17%	-$33.8M	16.63%	1
2022 Q2	$200M	Sell	4,093,785 -476,363	-10%	-$21.4M	20.05%	1
2022 Q1	$222M	Sell	4,570,148 -314,193	-6%	-$12.8M	15.31%	1
2021 Q4	$208M	Hold	4,884,341	–	–	12.56%	2
2021 Q3	$187M	Buy	4,884,341 +350,000	+8%	+$11.3M	8.41%	3
2021 Q2	$128M	Hold	4,534,341	–	–	5.54%	6
2021 Q1	$150M	Hold	4,534,341	–	–	5.27%	6
2020 Q4	$164M	Hold	4,534,341	–	–	7.31%	3
2020 Q3	$154M	Buy	+4,534,341	New	+$165M	8.88%	3

Other funds holding HRMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Vivo Capital's HRMY Position: Q4 2024 in Review

Vivo Capital sold out of Harmony Biosciences (HRMY) in Q4 2024, closing a stake of 2,606,247 shares — an estimated $104M sold.

Vivo Capital first reported a position in HRMY in Q3 2020 and held it in 17 quarters. The position peaked at $222M in Q1 2022. 247 funds tracked by Wall St. Rank hold HRMY as of Q4 2024.

Vivo Capital reported no remaining Harmony Biosciences position as of Q4 2024 after selling out during the quarter.
Vivo Capital sold 2,606,247 Harmony Biosciences shares in Q4 2024, an estimated $104M.
Vivo Capital first reported a position in Harmony Biosciences in Q3 2020 and held it in 17 quarters.
Vivo Capital's Harmony Biosciences position peaked at $222M in Q1 2022.
247 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2024.

Based on Vivo Capital's 13F filing for Q4 2024, filed 13 Feb 2025.